What are hybridomas used for in biotechnology?

Hybridomas are specialized cells that are used to produce monoclonal antibodies, which are identical copies of antibodies that target a specific antigen. This process involves fusing a specific type of immune cell, which produces antibodies, with a myeloma cell that can divide indefinitely. The resulting hybrid cell, or hybridoma, retains the ability to produce the desired antibody while also being able to replicate, creating a continuous supply of that antibody.

Monoclonal antibodies generated by hybridomas have various applications, including diagnostics, therapeutic treatments, and research. Their specificity allows them to be used in targeted therapies against diseases such as cancer, making them incredibly valuable in both clinical and laboratory settings.

The other options do not accurately represent the primary use of hybridomas. Hybridomas are not primarily involved in producing enzymes, enhancing plant growth, or directly modifying DNA. These processes pertain to different areas of biotechnology and involve distinct methods and technologies that do not incorporate the hybridoma technique.